We are developing safe and innovative drugs that improve mitochondrial health.


 
iStock-918470792.jpg
 
iStock-521497656.jpg
 

Focus on NASH 

Nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease, results from fat accumulation, injury (ballooning) and inflammation in the liver. NASH can lead to liver cirrhosis or liver cancer. Scientists at Continuum are developing novel drugs as innovative treatments for NASH.


 
iStock-521497656.jpg
 

Targeting Metabolic Disease & Disorders

Continuum Biosciences, Inc. is focused on improving how our bodies burn fuel. As we age, our metabolic rate declines and our bodies lose capacity for burning energy. This can result in excess nutrient storage and associated diseases including obesity, diabetes, fatty liver disease and other secondary conditions.

Scientists at Continuum have discovered new molecules that increase energy expenditure by targeting mitochondrial function. Continuum’s chemists are using multiple approaches to fine-tune the effectiveness and safety of their compounds for human use. These molecules have the potential to treat multiple diseases. Continuum is first targeting the fatty liver disease NASH.

 
iStock-182740074.jpg

 

Continuum Biosciences is a daughter company of Life Biosciences, which owns multiple biotechnology companies each focusing on a different hallmark of aging.